Amgen’s March Madness: ESAs, Nplate To Get FDA Advisory Panel Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Schering’s PegIntron in melanoma will also be reviewed at March 12-13 meeting of FDA’s Oncologic Drugs Advisory Committee.
You may also be interested in...
ODAC Review Of Schering-Plough’s PegIntron For Melanoma Postponed
Expected review of firm’s supplemental BLA for adjuvant treatment of melanoma postponed as FDA requests additional data.
ODAC Review Of Schering-Plough’s PegIntron For Melanoma Postponed
Expected review of firm’s supplemental BLA for adjuvant treatment of melanoma postponed as FDA requests additional data.
European Regulators Approve Labeling Update For Amgen’s Aranesp
Revised European ESA prescribing information consistent with proposal released last fall.